A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

This Phase III study tests a new drug called YL201 in people with small cell lung cancer (SCLC) that has come back or stopped responding to prior treatments. SCLC is an aggressive form of lung cancer, and new treatment options are urgently needed for patients whose disease has relapsed. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with small cell lung cancer (SCLC) confirmed by biopsy - Your cancer has come back after prior treatment - You are in good physical health (ECOG performance status 0 or 1) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have untreated or active spread of cancer to the brain or spinal cord - You have had serious immune-related side effects from prior immunotherapy - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.